Resource Summary Report

Generated by NIF on Sep 13, 2026

MDA-MB-361

RRID:CVCL_0620
Type: Cell Line

Proper Citation

RRID:CVCL_0620

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0620

Proper Citation: RRID:CVCL_0620

Description: Cell line MDA-MB-361 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: PMID:730202, PMID:833871, PMID:3518877, PMID:6935474, PMID:7272986, PMID:9671407, PMID:10862037, PMID:10969801, PMID:11044355, PMID:11343771, PMID:12800145, PMID:15677628, PMID:16397213, PMID:16541312, PMID:17157791, PMID:17334996, PMID:18516279, PMID:19582160, PMID:19593635, PMID:20070913, PMID:20164919, PMID:20215515, PMID:22460905, PMID:22585861, PMID:23601657, PMID:24094812, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28889351, PMID:29273624, PMID:30894373, PMID:30971826, PMID:31068700, PMID:35839778

Comments: Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-361

Synonyms: MDA-MB 361, MDA MB 361, MDA-MB361, MDAMB361, MDA-361, MDA361, MB361, MD Anderson-Metastatic Breast-361

Cross References: BTO:BTO_0001569, CLO:CLO_0007636, EFO:EFO_0001211, CLDB:cl3406, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-27, BCRC:60549, BioGRID_ORCS_Cell_line:1048, BioSample:SAMN03472909, BioSample:SAMN10987900, cancercelllines:CVCL_0620, CCRID:1101HUM-PUMC000381, Cell_Model_Passport:SIDM00528, ChEMBL-Cells:CHEMBL3308405, ChEMBL-Targets:CHEMBL614129, CLS:305267, Cosmic:687495, Cosmic:809235, Cosmic:871147, Cosmic:904379, Cosmic:908121, Cosmic:934527, Cosmic:979709, Cosmic:997919, Cosmic:1000124, Cosmic:1010928, Cosmic:1017160, Cosmic:1018464, Cosmic:1046933, Cosmic:1047695, Cosmic:1136355, Cosmic:1176627, Cosmic:1287895, Cosmic:1289397, Cosmic:1308994, Cosmic:1348961, Cosmic:1434953, Cosmic:1523777, Cosmic:1603220, Cosmic:1609461, Cosmic:2165011, Cosmic:2301529, Cosmic-CLP:908121, DepMap:ACH-000934, ECACC:92020423, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:908121, GEO:GSM73751, GEO:GSM115119, GEO:GSM155208, GEO:GSM186437, GEO:GSM186438, GEO:GSM186439, GEO:GSM217587, GEO:GSM274655, GEO:GSM344350, GEO:GSM344400, GEO:GSM350546, GEO:GSM421875, GEO:GSM481306, GEO:GSM783952, GEO:GSM827280, GEO:GSM847402, GEO:GSM847494, GEO:GSM887296, GEO:GSM888371, GEO:GSM1008906, GEO:GSM1053728, GEO:GSM1172890, GEO:GSM1172980, GEO:GSM1238121, GEO:GSM1264070, GEO:GSM1264072, GEO:GSM1264112, GEO:GSM1264114, GEO:GSM1374653, GEO:GSM1374654, GEO:GSM1374655, GEO:GSM1401664, GEO:GSM1670082, GEO:GSM2258758, GEO:GSM2258759, GEO:GSM2258760, GEO:GSM2258761, GEO:GSM2258762, GEO:GSM2258763, GEO:GSM2258764, GEO:GSM2258765, GEO:GSM2258766, GEO:GSM2258767, GEO:GSM2258768, GEO:GSM2258769, GEO:GSM2258770, GEO:GSM2258771, GEO:GSM2258772, GEO:GSM2258773, GEO:GSM2258774, GEO:GSM2258775, GEO:GSM2258935, GEO:GSM2258936, GEO:GSM2258937, IARC_TP53:18373, IARC_TP53:21128, LiGeA:CCLE_872, LINCS_HMS:50331, LINCS_LDP:LCL-1468, NCBI_Iran:C433, PharmacoDB:MDAMB361_902_2019, PRIDE:PXD030304, Progenetix:CVCL_0620, PubChem_Cell_line:CVCL_0620, SLKBase:3600, Wikidata:Q54904626

ID: CVCL_0620

Record Creation Time: 20220427T220755+0000

Record Last Update: 20260913T004833+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-361.

No alerts have been found for MDA-MB-361.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 520 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. Cell reports, 45(2), 116882.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Gao A, et al. (2026) Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer. Cancer research, 86(13), 3287.

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. Cell chemical biology, 33(6), 785.

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. International journal of cancer, 156(8), 1606.

Alam R, et al. (2025) Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer discovery, 15(4), 818.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(7), 1275.

Olsen SN, et al. (2025) Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. Cell reports. Medicine, 6(7), 102192.

Zidel A, et al. (2025) Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. Scientific reports, 15(1), 16964.

Mahdi AF, et al. (2025) Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. International journal of molecular sciences, 26(2).

Lombardi V, et al. (2025) PatientProfiler: building patient-specific signaling models from proteogenomic data. Molecular systems biology, 21(12), 1845.

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. Cancer research communications, 5(6), 981.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell chemical biology.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T??cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer cell.

Montero-Vergara J, et al. (2024) GRB2 is a BECN1 interacting protein that regulates autophagy. Cell death & disease, 15(1), 14.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Developmental cell, 59(5), 579.

Leuzzi G, et al. (2024) SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell, 187(4), 861.

Moyer CL, et al. (2024) IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(11), 2558.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity, 57(7), 1514.

Rybinska I, et al. (2024) SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness. International journal of cancer.